Breast Cancer Clinical Data Accepted for Oral Presentation

    TORONTO, Oct. 21 /CNW/ - Predictive medicine company PreMD Inc. (TSX:
PMD; today announced that an abstract entitled, "Quantitative
Galactose Oxidase Schiff's reaction in Nipple Aspirate Fluid may distinguish
women with or without Breast Cancer" has been accepted for an oral
presentation at the 4th Annual Academic Surgical Congress.
    "We are extremely pleased and honored that this abstract has been
accepted for presentation at this influential symposium," said Brent Norton,
President and CEO of PreMD Inc. "This study provides valuable clinical insight
as to how women with breast cancer may benefit from testing with Galactose
Oxidase Schiff's (GOS) reactivity. This presentation further strengthens our
clinical data of our entire cancer franchise, which we are progressively
    This study extends our scientific data and evaluates GOS reactivity in
healthy control patients compared to those with ductal carcinoma in situ or
invasive disease. The lead author on the study is Dr. Anees B. Chagpar from
the University of Louisville. The 4th Annual Academic Surgical Congress is to
be held February 3-6, 2009 in Fort Myers, FL

    About PreMD Inc.

    PreMD Inc. is a leader in predictive medicine, dedicated to developing
rapid, non-invasive tests for the early detection of life-threatening
diseases. PreMD's cardiovascular products include PREVU(*) POC and PREVU(*) LT,
both non-invasive skin cholesterol tests. The Company's cancer tests include
ColorectAlert(TM), LungAlert(TM) and a breast cancer test. PreMD's head office
is located in Toronto, Ontario and its research and product development
facility is at McMaster University in Hamilton, Ontario. For more information
about PreMD, please visit

    This press release contains forward-looking statements. These statements
involve known and unknown risks and uncertainties, which could cause the
Company's actual results to differ materially from those in the
forward-looking statements. Such risks and uncertainties include, among
others, the successful development or marketing of the Company's products, the
competitiveness of the Company's products if successfully commercialized, the
lack of operating profit and availability of funds and resources to pursue R&D
projects, the successful and timely completion of clinical studies, product
liability, reliance on third-party manufacturers, the ability of the Company
to take advantage of business opportunities, uncertainties related to the
regulatory process, and general changes in economic conditions. In addition,
while the Company routinely obtains patents for its products and technology,
the protection offered by the Company's patents and patent applications may be
challenged, invalidated or circumvented by our competitors and there can be no
guarantee of our ability to obtain or maintain patent protection for our
products or product candidates. Investors should consult the Company's
quarterly and annual filings with the Canadian and U.S. securities commissions
for additional information on risks and uncertainties relating to the
forward-looking statements.
    Investors are cautioned not to rely on these forward-looking statements.
PreMD is providing this information as of the date of this press release and
does not undertake any obligation to update any forward-looking statements
contained in this press release as a result of new information, future events
or otherwise.

    %SEDAR: 00007927E          %CIK: 0001179083

For further information:

For further information: Ron Hosking, Vice-President Finance and CFO,
Tel: (416) 222-3449 ext. 24, Email:; Brent Norton,
President & CEO, Tel: (416) 222-3449 ext 22, Email:

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890